Key Takeaways
- Kerry has opened a new Biotechnology Centre in Leipzig, Germany, focusing on innovative solutions for food and pharmaceuticals.
- The center will enhance enzyme development and bioprocessing, building on Kerry’s existing biotech products like ACRYLERASE™ and BIOBAKE™.
- This initiative aligns with Kerry’s sustainable nutrition strategy, supported by over 100 scientists and led by Dr. Marc Struhalla.
Overview of the New Biotechnology Centre
Kerry, a leading company in taste and nutrition, has inaugurated its Biotechnology Centre in Leipzig, Germany. This facility is designed to develop advanced biotechnology solutions for the food, beverage, and pharmaceutical sectors. Its primary activities will encompass enzyme identification, strain engineering, fermentation processes, and production scalability.
The centre aims to harness novel enzymes from nature, tailoring them for specific functions that can enhance product applications across industries. Kerry has successfully launched several groundbreaking biotech products, including ACRYLERASE™, which reduces acrylamide in instant coffee, DENARASE®, which streamlines the vaccine production process by eliminating residual DNA, and BIOBAKE™, a line of enzymes that improve the shelf life of baked goods.
These innovations in biotechnology are crucial for creating market solutions that improve efficiency, tackle ingredient shortages, and cater to specific consumer requirements. This aligns with Kerry’s ongoing commitment to enhance human health and product functionality.
Kerry has notably expanded its expertise in biotechnology through strategic acquisitions and investments. The Leipzig centre fortifies its global infrastructure and leverages the city’s rich biotechnology resources. Leipzig was chosen for this facility due to its robust skills base and research cluster, which includes c-LEcta, a firm acquired by Kerry in 2022 that specializes in enzymes and biotechnology.
The company’s biotechnology infrastructure now spans three continents and is coordinated from its Global Innovation Centre in Ireland. The Leipzig centre will be led by Dr. Marc Struhalla, the founder of c-LEcta, and will employ over 100 scientists, including 34 PhDs dedicated to research and development.
During the opening ceremony, Kerry CEO Edmond Scanlon highlighted the transformative potential of biotechnology for global markets. He remarked, “Kerry’s existing portfolio of biotech capabilities, built over the past 20 years, together with this new center, positions us to play a leading role in bringing the next generation of discoveries to market, addressing consumer demands for sustainable nutrition.”
Earlier in the year, Kerry also inaugurated a new manufacturing facility in Uganda, further expanding its global footprint in the biotechnology sector.
The content above is a summary. For more details, see the source article.